24-Dec-2025
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
TipRanks (Mon, 22-Dec 5:48 PM ET)
Business Wire (Wed, 17-Dec 8:30 AM ET)
Vistagen Appoints Nick Tressler as Chief Financial Officer
Business Wire (Mon, 1-Dec 8:30 AM ET)
Business Wire (Wed, 26-Nov 8:30 AM ET)
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
Business Wire (Thu, 13-Nov 4:30 PM ET)
Business Wire (Mon, 10-Nov 8:30 AM ET)
Vistagen to Participate in Stifel Healthcare Conference 2025
Business Wire (Wed, 5-Nov 8:30 AM ET)
Vistagen Completes Key Phase 3 Trial for Social Anxiety—PALISADE-3 Results to Arrive by Year End
Market Chameleon (Mon, 3-Nov 6:19 AM ET)
Business Wire (Mon, 3-Nov 8:30 AM ET)
Vistagen Appoints Paul Edick to its Board of Directors
Business Wire (Wed, 29-Oct 8:30 AM ET)
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.
As of December 24, 2025, VTGN stock price climbed to $0.73 with 1,650,314 million shares trading.
VTGN has a beta of 0.55, meaning it tends to be less sensitive to market movements. VTGN has a correlation of 0.00 to the broad based SPY ETF.
VTGN has a market cap of $28.75 million. This is considered a Sub-Micro Cap stock.
Last quarter Vistagen Therapeutics reported $258,000 in Revenue and -$.54 earnings per share. This fell short of revenue expectation by $-81,480 and missed earnings estimates by -$.07.
In the last 3 years, VTGN traded as high as $24.71 and as low as $.68.
The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL, IWC, AVSC.
VTGN has underperformed the market in the last year with a price return of -71.7% while the SPY ETF gained +17.3%. VTGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.8% and -84.0%, respectively, while the SPY returned +4.4% and +1.4%, respectively.
VTGN support price is $.66 and resistance is $.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.
